Vicebio Secures Major Funding to Develop Vaccines for Respiratory Diseases
Funding for Respiratory Disease Vaccines
Vicebio, a UK-based vaccine company, recently completed a $100 million series B funding round led by TCGX, with contributions from Goldman Sachs Alternatives, Avoro Ventures, venBio, and others. This significant funding aims to advance Vicebio's innovative multivalent vaccine candidates.
Molecular Clamp Technology Explained
Molecular clamp technology enhances the efficacy of vaccines by stabilizing viral surface proteins in their prefusion state. This approach is critical for generating robust immune responses. Emmanuel Hanon, CEO of Vicebio, noted that the technology enables strong protective responses against pathogens by keeping the viral glycoproteins in the most immunogenic conformation.
Market Trends and Future Directions
- The respiratory vaccine market is projected to reach nearly $70 billion by 2024.
- Investment in respiratory virus vaccine development has seen a notable increase.
- There is a rising need for vaccines that can protect against multiple respiratory pathogens, particularly for high-risk groups.
For more information about the potential of Vicebio's vaccine technology and its impact on public health, consider visiting additional resources.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.